Telikibart

泰利奇拜单抗

Report date: 2026/03/24 20:00:35

Base Information

Drug NameTelikibart
Drug Alias NameGR-1802GR1802
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-Interleukin-4 receptor subunit alpha
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaDermatitis, Atopic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesGenrix (Shanghai) Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaDermatitis, Atopic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A